Joint Clinical Trials Office
Do More, Feel Better: Lay-delivered Behavioral Activation in Senior Centers
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 17, 2024
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal Onset Seizures
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
A Two-tiered, Phase II, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) for the Treatment of Anemic Patients with Philadelphia Chromosome-negative Myeloproliferative Neoplasms
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): IMPACT Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic TNBC
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
Technical Development for Fetal and Neonatal MRI
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 7, 2024
Assessment of Placental Perfusion and Oxygenation Using Novel MRI Approaches
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 7, 2024
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2024
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of KB707 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2024